ArticleInternational journal of pharmaceutics2016
Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia.
Article in International journal of pharmaceutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- Ex Vivo Characterization and In Vivo Nasal Delivery of Ropinirole-Loaded PEO-b-PCL/Tween 80/β-Cyclodextrin Systems in C57BL/6J Mice.Molecules (Basel, Switzerland) · 2026Article
- Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia.Journal of clinical medicine · 2025Review
- Advanced P407/Tw80/βCD based Nasal Powders of Ropinirole Hydrochloride for Nose-to-Brain Delivery in Parkinson's Disease: Preparation and Comprehensive In Vitro and Ex Vivo Evaluation.The AAPS journal · 2025Article
- Advances in Aerosol Formulation for Targeted Delivery of Therapeutic Agents from Nose to Brain.Current drug delivery · 2025Review
- Fabricating Polymer/Surfactant/Cyclodextrin Hybrid Particles for Possible Nose-to-Brain Delivery of Ropinirole Hydrochloride: In Vitro and Ex Vivo Evaluation.International journal of molecular sciences · 2024Article
- Article
- Development and In Vitro-Ex Vivo Evaluation of Novel Polymeric Nasal Donepezil Films for Potential Use in Alzheimer's Disease Using Experimental Design.Pharmaceutics · 2022Article
- Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs.Molecular pharmaceutics · 2021Article
- Versatile Nasal Application of Cyclodextrins: Excipients and/or Actives?Pharmaceutics · 2021Review
- Nasal Powder Formulations: In-Vitro Characterisation of the Impact of Powders on Nasal Residence Time and Sensory Effects.Pharmaceutics · 2021Article
- Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity.Molecules (Basel, Switzerland) · 2020Article
- In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates.Drug delivery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
In this work nasal powder formulations of thalidomide were designed and studied to be used by persons affected by hereditary hemorrhagic telangiectasia as a complementary anti-epistaxis therapy, with the goal of sustaining the effect obtained with thalidomide oral treatment after its discontinuation for adverse effects. Three nasal powders were prepared using as carriers β-CD or its more hydrophilic derivatives such as hydropropyl-β-CD and sulphobutylether-β-CD and tested with respect to technological and biopharmaceutical features after emission with active and passive nasal powder devices. For all formulated powders, improved dissolution rate was found compared to that of the raw material, making thalidomide promptly available in the nasal environment at a concentration favouring an accumulation in the mucosa. The very limited transmucosal transport measured in vitro suggests a low likelihood of significant systemic absorption. The topical action on bleeding could benefit from the poor absorption and from the fact that about 2-3% of the thalidomide applied on the nasal mucosa was accumulated within the tissue, particularly with the β-CD nasal powder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.